

Contacts Media

Amsterdam +31 20 721 4133
Dublin +33 1 70 48 24 45
Milan +39 02 72 42 62 12
Paris +33 1 70 48 24 45

Brussels +32 2 620 15 50
Lisbon +351 210 600 614
Oslo +47 22 34 19 15

Contact Investor Relations

+33 1 70 48 24 27

Laboratorio Farmaceutico Erfo S.p.A. lists on Euronext Growth Milan

- **Ninth listing of 2022 on Euronext Growth Milan**
- **Laboratorio Farmaceutico Erfo S.p.A. brings the total number of companies listed on Euronext Growth Milan to 179**
- **Total placement volume of the offering equal to €3.45 million**



Milan – 29 June 2022 – Borsa Italiana, part of the Euronext Group, today congratulates Laboratorio Farmaceutico Erfo S.p.A on its listing on Euronext Growth Milan.

Laboratorio Farmaceutico Erfo S.p.A is an innovative SME operating in the nutraceutical sector. The company specialises in the formulation and production of food supplements which, thanks to continuous R&D carried out internally and in collaboration with the University of Rome's "Campus Bio-Medico" and the University of Messina, are marketed following market trends and consumer needs.

Laboratorio Farmaceutico Erfo S.p.A represents the ninth listing since the beginning of the year on Borsa Italiana's market dedicated to small and medium sized companies, and it brings the total number of firms currently listed on Euronext Growth Milan to 179.

In the placement phase, Laboratorio Farmaceutico Erfo S.p.A raised €3.0 million excluding the potential exercise of an over-allotment option. In the case of the full exercise of the over-allotment option, the total amount raised will be €3.45 million.

The free float at the time of admission was 22.22% and the market capitalisation at IPO was €13.5 million.

Alex Cutè, CEO and Founder of Laboratorio Farmaceutico Erfo S.p.A., said: *"It is a source of pride and satisfaction for me to celebrate the achievement of this ambitious goal. The listing of ERFO is an important step along the journey towards internationalisation. The IPO's proceeds will accelerate the achievement of our strategic objectives, aimed at consolidating our business model, characterised by a high degree of innovation and scalability. We have a solid financial base that in 2021 allowed us to grow at a CAGR of 26% during 2013-21, together with high profitability and zero debt."*



Caption: Alex Cutè, CEO and Founder, rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.

CONTACTS MEDIA – italypressoffice@euronext.com

Andrea Monzani (Milan/Rome)

Federica Marotti (Milan/Rome)

Ester Russom (Milan/Rome)

+39 02 72 42 62 12

About Laboratorio Farmaceutico Erfo S.p.A.

Laboratorio Farmaceutico Erfo S.p.A., founded in 2013, is an innovative SME operating in the nutraceutical sector. The company specialises in the formulation and production of food supplements which, thanks to continuous R&D carried out internally and in collaboration with the University of Rome "Campus Bio-Medico" and the University of Messina, are commercialised following the market trends and consumer needs. The Company has over 60 products in its portfolio manufactured through the use of latest generation industrial machinery.

The business model is developed through two strategic lines:

1. Diètnatural: business format franchise dedicated to the sale of nutraceutical products and ongoing assistance in the nutritional journey of each customer, through versatile and high-margin commercial formulas. These products, marketed under the "Diètnatural" brand, are distributed in proprietary single-brand centres, both owned and managed by franchisees.

2. Medical Division: new line of nutraceutical products launched in 2021, which are mainly distributed through pharmaceutical wholesalers to pharmacies and para-pharmacies. This business unit is dedicated to specific therapeutic areas: gastroenterology and urology.

About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed equity issuers and around €6.6 trillion in market capitalisation as of end March 2022, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.

For the latest news, go to euronext.com or follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this



date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.

